

ASX ANNOUNCEMENT

21 January 2025

## Results of Extraordinary General Meeting

**Melbourne, Australia; 21 January 2025:** Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), advises that its Extraordinary General Meeting of Shareholders was held today at Becketts Lawyers, Level 34, 120 Collins Street, Melbourne, VIC 3000 at 12.00 pm AEDT.

The resolutions were voted in accordance with the Notice of Extraordinary General Meeting previously advised to the Australian Securities Exchange.

Resolutions 1 to 6 were carried on a poll.

Further information required by section 251AA(2) of the *Corporations Act 2001 (Cth)* is attached.

-ENDS-

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**

**CONTACTS:** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, [kilian.kelly@cynata.com](mailto:kilian.kelly@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [lauren@itttlebigdeal.au](mailto:lauren@itttlebigdeal.au)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3 – patient enrolment completed) and diabetic foot ulcers (DFU – patient enrolment completed) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**

# Disclosure of Proxy Votes

Cynata Therapeutics Limited

Extraordinary General Meeting

Tuesday, 21 January 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of issue of Shares under the Placement	P	45,308,956	42,714,230 94.27%	2,438,887 5.38%	26,639,604	155,839 0.34%	42,920,069 94.62%	2,438,887 5.38%	26,639,604	Carried
2 Approval to issue Shares to Dr Geoff Brooke under the Director Placement	P	77,211,166	73,655,162 95.39%	3,403,325 4.41%	278,343	152,679 0.20%	73,857,841 95.60%	3,403,325 4.40%	278,343	Carried
3 Approval to issue Shares to Dr Kilian Kelly under the Director Placement	P	76,848,858	73,292,854 95.37%	3,403,325 4.43%	640,651	152,679 0.20%	73,495,533 95.57%	3,403,325 4.43%	640,651	Carried
4 Approval to issue Shares to Dr Darryl Maher under the Director Placement	P	77,468,509	73,912,505 95.41%	3,403,325 4.39%	21,000	152,679 0.20%	74,065,184 95.61%	3,403,325 4.39%	71,000	Carried
5 Approval to issue Shares to Ms Janine Rolfe under the Director Placement	P	77,352,230	73,796,226 95.40%	3,403,325 4.40%	137,279	152,679 0.20%	73,998,905 95.60%	3,403,325 4.40%	137,279	Carried
6 Approval to issue Shares to Dr Paul Wotton under the Director Placement	P	77,468,509	73,702,482 95.14%	3,613,348 4.66%	21,000	152,679 0.20%	73,905,161 95.34%	3,613,348 4.66%	21,000	Carried

For personal use only

